Abstract
Over the past decade, fragment-based drug discovery has developed significantly and has gained increasing popularity in the pharmaceutical industry as a powerful alternative and complement to traditional high-throughput screening approaches for hit identification. Fragment-based methods are capable of rapidly identifying starting points for structure-based drug design from relatively small libraries of low molecular weight compounds. The main constraints are the need for sensitive methods that can reliably detect the typically weak interactions between fragments and the target protein, and strategies for transforming fragments into higher molecular weight drug candidates. This approach has recently been validated as series of compounds from various programs have entered clinical trials.
Keywords: Fragment screening, Ligand efficiency, Drug discovery, Cancer, high-throughput screening (HTS), Crystallography, fluorimetry, Phosphoinositide-Dependent Kinase-1 (PDK1), Anti-cancer, Cyclindependent kinase (CDK)
Anti-Cancer Agents in Medicinal Chemistry
Title: Targeting Cancer Using Fragment Based Drug Discovery
Volume: 12 Issue: 1
Author(s): Andrew P. Turnbull and Susan M. Boyd
Affiliation:
Keywords: Fragment screening, Ligand efficiency, Drug discovery, Cancer, high-throughput screening (HTS), Crystallography, fluorimetry, Phosphoinositide-Dependent Kinase-1 (PDK1), Anti-cancer, Cyclindependent kinase (CDK)
Abstract: Over the past decade, fragment-based drug discovery has developed significantly and has gained increasing popularity in the pharmaceutical industry as a powerful alternative and complement to traditional high-throughput screening approaches for hit identification. Fragment-based methods are capable of rapidly identifying starting points for structure-based drug design from relatively small libraries of low molecular weight compounds. The main constraints are the need for sensitive methods that can reliably detect the typically weak interactions between fragments and the target protein, and strategies for transforming fragments into higher molecular weight drug candidates. This approach has recently been validated as series of compounds from various programs have entered clinical trials.
Export Options
About this article
Cite this article as:
P. Turnbull Andrew and M. Boyd Susan, Targeting Cancer Using Fragment Based Drug Discovery, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (1) . https://dx.doi.org/10.2174/187152012798764660
DOI https://dx.doi.org/10.2174/187152012798764660 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Infection and Malignancy Risk in Patients Treated with TNF Inhibitors for Immune-Mediated Inflammatory Diseases
Current Drug Safety How Much Gets there and What Does it Do?: The Need for Better Pharmacokinetic and Pharmacodynamic Endpoints in Contemporary Drug Discovery and Development
Current Pharmaceutical Design Two Orthogonal Approaches to Overcome Multi-Drug Resistant HIV-1s: Development of Protease Inhibitors and Entry Inhibitors Based on CXCR4 Antagonists
Current Drug Targets - Infectious Disorders Bioconjugation of Polymers: A Novel Platform for Targeted Drug Delivery
Current Pharmaceutical Design AMPA Receptor Antagonists: Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) Inflammatory Bowel Disease: Etiology, Pathogenesis and Current Therapy
Current Pharmaceutical Design Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia Patients
Current Pharmaceutical Biotechnology Genetic Vaccination for the Immunotherapy of B-Cell Malignancies
Current Gene Therapy Novel Agents Targeting Bioactive Sphingolipids for the Treatment of Cancer
Current Medicinal Chemistry A Partial Least Squares Algorithm for Microarray Data Analysis Using the VIP Statistic for Gene Selection and Binary Classification
Current Bioinformatics Preparation and Preliminary Evaluation of <sup>68</sup>Ga-Acridine: An Attempt to Study the Potential of Radiolabeled DNA Intercalator as a PET Radiotracer for Tumor Imaging
Anti-Cancer Agents in Medicinal Chemistry Molecular Kinetics and Targeting Within the Nucleus
Current Chemical Biology Therapeutic Proteins: A to Z
Protein & Peptide Letters Identifying Molecular Targets Mediating the Anticancer Activity of Histone Deacetylase Inhibitors: A Work in Progress
Current Cancer Drug Targets Topomer CoMFA 3D-QSAR and Docking Studies of Pyrimidine Inhibitors of Pneumocystis Carinii Dihydrofolate Reductase
Letters in Drug Design & Discovery Gadd45 Proteins as Critical Signal Transducers Linking NF-κB to MAPK Cascades
Current Cancer Drug Targets JAK/STAT Signal Transduction: Promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases
Current Drug Targets Weight Optimized Neural Network Using Metaheuristics for the Classification of Large Cell Carcinoma and Adenocarcinoma from Lung Imaging
Current Signal Transduction Therapy Never Sleep with Baby? Or Keep Me Close But Keep Me Safe: Eliminating Inappropriate “Safe Infant Sleep” Rhetoric in the United States
Current Pediatric Reviews Patent Analysis as a Tool for Research Planning: Study on Natural Based Therapeutics Against Cancer Stem Cells
Recent Patents on Anti-Cancer Drug Discovery